197 related articles for article (PubMed ID: 1808921)
21. Does the HIV-1deltakURNe vaccine strain hold the key to curbing HIV infection? An interview with Ronald Desrosiers, PhD.
Desrosiers R
J Int Assoc Physicians AIDS Care; 1998 Mar; 4(3):45-6. PubMed ID: 11365180
[TBL] [Abstract][Full Text] [Related]
22. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
[TBL] [Abstract][Full Text] [Related]
23. Immunisation with gp160 in HIV-1 infection.
Fiala C; Stewart GT
Lancet; 1999 Sep; 354(9182):948; author reply 949. PubMed ID: 10489976
[No Abstract] [Full Text] [Related]
24. The HIV vaccine pipeline, from preclinical to phase III.
Schultz AM; Bradac JA
AIDS; 2001; 15 Suppl 5():S147-58. PubMed ID: 11816163
[No Abstract] [Full Text] [Related]
25. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
[TBL] [Abstract][Full Text] [Related]
26. Update on HIV vaccines.
Meldorf M; Corey L
STEP Perspect; 1997; 9(2):5-6, 8-9. PubMed ID: 11364929
[TBL] [Abstract][Full Text] [Related]
27. Public health. A sound rationale needed for phase III HIV-1 vaccine trials.
Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA
Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576
[No Abstract] [Full Text] [Related]
28. Evidence as a HIV-1 self-defense vaccine of cyclic chimeric dodecapeptide warped from undecapeptidyl arch of extracellular loop 2 in both CCR5 and CXCR4.
Misumi S; Takamune N; Ido Y; Hayashi S; Endo M; Mukai R; Tachibana K; Umeda M; Shoji S
Biochem Biophys Res Commun; 2001 Aug; 285(5):1309-16. PubMed ID: 11478800
[TBL] [Abstract][Full Text] [Related]
29. Outstanding questions on HIV vaccine trial.
Jefferys R; Harrington M
Science; 2004 Jul; 305(5681):180; author reply 180. PubMed ID: 15247456
[No Abstract] [Full Text] [Related]
30. HIV gp120-specific cell-mediated immune responses in mice after oral immunization with recombinant Salmonella.
Berggren RE; Wunderlich A; Ziegler E; Schleicher M; Duke RC; Looney D; Fang FC
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):489-95. PubMed ID: 8548327
[TBL] [Abstract][Full Text] [Related]
31. Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use.
Thomson SA; Jaramillo AB; Shoobridge M; Dunstan KJ; Everett B; Ranasinghe C; Kent SJ; Gao K; Medveckzy J; Ffrench RA; Ramshaw IA
Vaccine; 2005 Sep; 23(38):4647-57. PubMed ID: 15964105
[TBL] [Abstract][Full Text] [Related]
32. Prime-boost immunization strategies against HIV.
Barnett SW; Klinger JM; Doe B; Walker CM; Hansen L; Duliège AM; Sinangil FM
AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S299-309. PubMed ID: 9814958
[No Abstract] [Full Text] [Related]
33. Support for the RV144 HIV vaccine trial.
Belshe R; Franchini G; Girard MP; Gotch F; Kaleebu P; Marthas ML; McChesney MB; McCullough R; Mhalu F; Salmon-Ceron D; Sekaly RP; van Rompay K; Verrier B; Wahren B; Weissenbacher M
Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15247455
[No Abstract] [Full Text] [Related]
34. [Construction and study of antigenic characteristics of recombinant salmonella strain producing TBI protein].
Karpenko LI; Ignat'ev GM; Agafonov AP; Poryvaeva VA; Lebedev LP; Veremeĭko TA; Nekrasova NA; Klimov NA; Kozlov AP; Il'ichev AA
Vopr Virusol; 2002; 47(2):25-8. PubMed ID: 12046463
[TBL] [Abstract][Full Text] [Related]
35. Vaccine to prevent AIDS overstated.
Lewis D
Res Initiat Treat Action; 1999 Jan; 5(1):11-2. PubMed ID: 11366223
[TBL] [Abstract][Full Text] [Related]
36. The challenges of HIV vaccine development and testing.
Burgers WA; Williamson C
Best Pract Res Clin Obstet Gynaecol; 2005 Apr; 19(2):277-91. PubMed ID: 15778116
[TBL] [Abstract][Full Text] [Related]
37. HIV-1/AIDS vaccine development: are we in the darkness.
Qiu C; Xu JQ
Chin Med J (Engl); 2008 May; 121(10):939-45. PubMed ID: 18706210
[No Abstract] [Full Text] [Related]
38. What hope is there for an HIV vaccine?
Witten G
S Afr Med J; 2004 Oct; 94(10):831. PubMed ID: 15532757
[No Abstract] [Full Text] [Related]
39. No vaccine against HIV yet--are we not perfectly equipped?
Singh M
Virol J; 2006 Aug; 3():60. PubMed ID: 16939652
[TBL] [Abstract][Full Text] [Related]
40. Novel strategies toward the development of an effective vaccine to prevent human immunodeficiency virus infection or acquired immunodeficiency virus.
Ensoli B; Cafaro A
AIDS Clin Rev; 2000-2001; ():23-61. PubMed ID: 10999215
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
